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Background: Pre-pregnancy obesity, excess gestational weight gain (GWG), and
gestational diabetes (GDM) increase fetal growth. Our aim was to assess whether normal
GWG is associated with lower risk for a large-for-gestational-age (LGA; over the 90th
percentile of birth weight for sex and gestational age) infant and lower birth weight
standard deviation (SD) score in the presence of GDM and maternal obesity.
Methods: This multicenter case-control study is part of the Finnish Gestational Diabetes
(FinnGeDi) Study and includes singleton pregnancies of 1,055 women with GDM
and 1,032 non-diabetic controls. Women were divided into 12 subgroups according
to their GDM status, pre-pregnancy body mass index (BMI; kg/m2), and GWG.
Non-diabetic women with normal BMI and normal GWG (according to Institute of
Medicine recommendations) served as a reference group.
Results: The prevalence of LGA birth was 12.2% among women with GDM and
6.2% among non-diabetic women (p < 0.001). Among all women, normal GWG
was associated with lower odds of LGA [odds ratio (OR) 0.57, 95% CI: 0.41–0.78].
Among women with both obesity and GDM, the odds for giving birth to a LGA infant
was 2.25-fold (95% CI: 1.04–4.85) among those with normal GWG and 7.63-fold
(95% CI: 4.25–13.7) among those with excess GWG compared with the reference group.
Compared with excess GWG, normal GWG was associated with 0.71 SD (95% CI:
0.47–0.97) lower birth weight SD score among women with GDM and obesity. Newborns
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of normal weight women with GDM and normal GWG had 0.28 SD (95% CI: 0.05–
0.51) lower birth weight SD scores compared with their counterparts with excess GWG.
In addition, in the group of normal weight non-diabetic women, normal GWG was
associated with 0.46 SD (95% CI: 0.30–0.61) lower birth weight SD scores compared
with excess GWG.
Conclusion: GDM, obesity, and excess GWG are associated with higher risk for LGA
infants. Interventions aiming at normal GWG have the potential to lower LGA rate and
birth weight SD scores even when GDM and obesity are present.
Keywords: gestational diabetes, gestational weight gain, obesity, birthweight, birth weight SD, large-for-
gestational age
INTRODUCTION
Gestational diabetes (GDM) affects 10–25% of all pregnancies
depending on diagnostic criteria, screening strategies, and study
populations (1, 2). Along with GDM, pre-pregnancy obesity and
excess gestational weight gain (GWG) are major pregnancy-
related health problems. During pregnancy, GWG is an
important modifiable factor. Nearly half of all pregnant women
exceed the Institute of Medicine (IOM) recommendations for
GWG (3, 4).
GDM, pre-pregnancy obesity, and excess GWG are all
independent risk factors for having a large-for-gestational-age
(LGA) infant (4–7). Previous studies assessing the association of
GWG with LGA in relation to GDM and pre-pregnancy obesity
are inconsistent. One register-based study reported that higher
GWG was associated with higher risk for LGA among both
womenwith untreated GDMand among those without GDM (8).
Previous retrospective studies in a general population of full-term
singleton births reported that excess GWG was associated with
LGA, but the prevalence of GDM in these studies was low ranging
from 4.5 to 4.9% (5, 7). Other studies including only women with
GDM reported an increased risk for LGA in women with excess
GWG (6, 9–11).
Therefore, we studied whether GWG is associated with LGA
infants in women with and without GDM as categorized by pre-
pregnancy BMI. We hypothesized that normal GWG decreases
the risk of LGA in all BMI categories regardless of GDM status.
MATERIALS AND METHODS
The present multicenter case-control study is based on the
clinical-genetic arm of the Finnish Gestational Diabetes Study
(FinnGeDi), which has been described in detail (12, 13).
Briefly, 1,146 women with singleton pregnancies diagnosed with
GDM were recruited in delivery units before delivery, and
the next consenting non-diabetic mother (n = 1,066) giving
birth in the same hospital was recruited as a control. Women
were recruited between February 2009 and December 2012
in seven Finnish delivery hospitals. Comprehensive data on
Abbreviations: GWG, gestational weight gain; GDM, gestational diabetes; LGA,
large-for-gestational age; IOM, Institute ofMedicine; OGTT, oral glucose tolerance
test.
participants, pregnancy, delivery, and newborns were obtained
from hospital and maternal welfare clinic records, from a
detailed self-filled questionnaire, and from the Finnish Medical
Birth Register.
According to the national Finnish Current Care guidelines
introduced in 2008, an oral glucose tolerance test (OGTT) is
recommended to screen for GDM in every pregnant woman,
except those with very low-risk: (1) < 25 year-old primiparous
women with BMI < 25 kg/m2 and without a family history of
diabetes; and (2) < 40 year-old multiparous women with BMI
< 25 kg/m2 and without a history of GDM or a macrosomic
newborn (birth weight > 4,500 g) (14). GDM was diagnosed
using a 2-hour, 75 gOGTT that was primarily performed between
24 and 28 weeks of gestation. For high-risk groups (prior GDM,
BMI ≥ 35 kg/m2, glucosuria, family history of diabetes, or
polycystic ovary syndrome), OGTT was performed for the first
time between 12 and 16 weeks of gestation and, if normal,
repeated between 24 and 28 weeks of gestation. The diagnostic
criteria for the plasma glucose concentrations were≥ 5.3 mmol/l
after overnight fasting, ≥ 10.0 mmol/l at 1 h, or ≥ 8.6 mmol/l
at 2 h after the glucose load. The diagnosis of GDM was based
on one or more abnormal values in the OGTT. Additionally,
GDM diagnosis was based on glucose self-monitoring for 24
participants (12).
Information on maternal age at delivery, parity, and smoking
during pregnancy were obtained from the Finnish Medical Birth
Register, educational attainment from a questionnaire, and use
of insulin or metformin from the mother’s medical records.
Self-reported maternal height and weight before pregnancy, and
weight measured in the first and last antenatal visit were obtained
frommaternity welfare clinic records. Pre-pregnancy BMI< 25.0
kg/m2 was classified as normal, 25.0–29.9 kg/m2 as overweight,
and ≥ 30.0 kg/m2 as obese (15). Underweight women (BMI <
18.5 kg/m2) (n = 58, 2.8%) were categorized as normal in the
analysis. GWG was calculated as the difference between pre-
pregnancy weight and weight at the last antenatal visit. The
2009 IOM recommendations were used to classify normal and
excess weight gain during pregnancy in different pre-pregnancy
BMI categories (normal: 11.5–16.0 kg; overweight: 7.0–11.5 kg;
obese: 5.0–9.0 kg)11. Those women with GWG below the IOM
recommendations (n = 434, 20.8%) were classified as having
normal GWG in the final analysis.
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TABLE 1 | Characteristics of mothers and newborns (n = 2,087).
Characteristic Non-diabetic GDM P-valuea
n = 1,032 n = 1,055
Mean (SD)/n (%)
Mother
Age at delivery, years 29.5 (5.1) 32.0 (5.3) <0.001
Height, cm 165.4 (5.8) 164.8 (5.7) 0.029
Pre-pregnancy
weight, kg
64.6 (12.0) 76.5 (17.2) <0.001
Pre-pregnancy BMI,
kg/m2
23.6 (4.1) 28.1 (6.1) <0.001
Smoking during
pregnancy, n (%)
153 (14.8%) (1,031) 178 (16.9%) (1,051) 0.191
Education, (%) (908) (948)
Basic or less 40 (4.4%) 61 (6.4%) 0.054
Secondary 410 (45.2%) 438 (46.2%) 0.650
Lower-level tertiary 229 (25.2%) 255 (26.9%) 0.410
Upper-level tertiary 229 (25.2%) 194 (20.5%) 0.015
Primipara, n (%) 505 (48.9%) 455 (43.1%) 0.008
GWG, kgb 14.8 (5.1) 12.3 (5.8) <0.001
Excess GWGc, n (%) 470 (45.5%) 521 (49.4%) 0.079
Insulin and/or
metformin treatment
–(0.0%) 190 (18.0%) <0.001
Newborn
Birth weight, g 3,591 (471) 3,670 (477) <0.001
Birth weight SD −0.10 (0.98) 0.24 (1.10) <0.001
SGAd, n (%) 111 (10.8%) 94 (8.9%) 0.157
LGAe, n (%) 64 (6.2%) 129 (12.2%) <0.001
Gestational age at
birth, weeks
40.2 (1.2) 39.7 (1.2) <0.001
GDM, gestational diabetes; BMI, body mass index (kg/m2 ); GWG, gestational weight gain.
() Number of available information unless from all.
aThe t-test for continuous and chi-square test for categorical variables.
bDifference of (self-reported) pre-pregnancy weight and weight at the last antenatal visit
at 35 gestational weeks or later.
cExcess gestational weight gain based on Institute of Medicine 2009 criteria.
dSmall-for-gestational-age (birth weight under the 10th percentile for sex and
gestational age).
eLarge-for-gestational-age (birth weight over the 90th percentile for sex and
gestational age).
Data on birth weight (kg), birth length (cm), head
circumference (cm), and sex of the newborn were obtained from
the Finnish Medical Birth Register. The birth weight standard
deviation (SD) score is a sex- and parity-specific parameter
estimating birth weight and length in singletons born at 23–43
gestational weeks, according to Finnish standards (16). LGA was
defined as birth weight over the 90th percentile and small-for-
gestational-age (SGA) was defined as under the 10th percentile
for sex and gestational age.
Of all the 2,212 participants, 47 (2.1%) women with missing
GWG data and 78 (3.5%) women whose last antenatal weight
was measured before 35 weeks were excluded from the
analysis. In total, 1,055 women with GDM and 1,032 non-
diabetic controls were included in the analysis (Table 1). The
characteristics of women and their newborns were compared
in six groups categorized by GDM status (case or control) and
pre-pregnancy BMI (normal, overweight, obese) (Tables 2, 3).
Further, participants were divided into 12 subgroups according
to their GDM status, pre-pregnancy BMI, and GWG (normal
or excess) (Figure 1). The group of non-diabetic controls with
normal pre-pregnancy BMI and with normal GWG was used
as a reference group. The study was approved by the Ethics
Committee in Northern Ostrobothnia Hospital District in 2008.
Each participant provided written informed consent.
Statistical Analysis
Numbers and frequencies (%) are reported for categorical
variables and means (SD) for continuous variables. Linear
regression [difference in means with 95% confidence interval
(CI)] was used for continuous outcomes, and logistic regression
[odds ratios (ORs) with 95% CI] was used for categorical
outcomes. In the regression analyses, 11 subgroups categorized
by GDM status, BMI, and GWG (normal/excess) were compared
with the reference group (normal weight non-diabetic women
with normal GWG). The results were adjusted for age at delivery,
parity, smoking during pregnancy, and delivery hospital.
Educational attainment, which is a potential confounding
variable, was missing for 11.1% (n = 231) of the women; thus,
we performed a sub-analysis that included only the women
with valid education data. Since adjustment for educational
attainment did not essentially alter the associations, it was
excluded from the final analysis.
RESULTS
Characteristics of Women With and
Without GDM
Women with GDM tended to be older, shorter, and had higher
BMI than the non-diabetic women (Table 1). Eighty-two percent
(n = 865) of them were treated with diet, and 18% (n = 190)
with additional insulin and/or metformin. Of all GDM women,
65.0% were overweight or obese, the corresponding rate being
28.2% among non-diabetic women.
GDM women gained less weight during pregnancy than
non-diabetic women (Table 1). Among women with overweight,
the difference was 1.8 kg (p < 0.001), and among women
with obesity, the difference was 3.4 kg (p < 0.001) (Table 3).
Still, GWG was normal in 50.6% of the women in the GDM
group and in 54.4% of the women in the non-diabetic group
(Table 1). Of women with overweight or obesity, 60.5% in the
GDM group and 75.0% in the non-diabetic group exceeded
IOM recommendations for GWG (Table 2). In women with
overweight or obesity, GWG below the IOM guidelines was more
common in the GDM group, 16.0 vs. 7.2%, respectively (p <
0.001). Of the women with GDM, the prevalence of excess GWG
was 51.0% in the diet-treated women and 42.1% among women
who received additional medical treatment (p= 0.027).
Gestational Weight Gain and Fetal Growth
Large-for-Gestational Age
The prevalence of LGA was 12.2% among GDM women and
6.2% among non-diabetic women (p < 0.001) (Table 1). Among
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TABLE 2 | Characteristics of mothers and newborns in six groups categorized by GDM status and pre-pregnancy BMI (n = 2,087).
Number of subgroup 1 2 3 4 5 6
Non-diabetic + GDM + Non-diabetic + GDM + Non-diabetic + GDM +
BMI < 25.0 BMI < 25.0 BMI 25.0–29.9 BMI 25.0–29.9 BMI ≥ 30.0 BMI ≥ 30.0
n = 741 n = 369 n = 208 n = 336 n = 83 n = 350
Mean (SD)/n (%)
Mother
Age at delivery, years 29.3 (5.1) 31.7 (5.2) 30.5 (5.2) 32.4 (5.3) 29.1 (5.2) 31.8 (5.4)
Height, cm 165.4 (5.8) 165.0 (5.9) 165.4 (6.3) 164.7 (5.7) 165.1 (5.4) 164.7 (5.7)
Pre-pregnancy weight, kg 59.1 (6.8) 60.8 (6.8) 73.7 (6.5) 73.8 (6.6) 90.9 (10.3) 95.5 (13.4)
Pre-pregnancy BMI, kg/m2 21.6 (2.0) 22.3 (1.9) 26.9 (1.4) 27.2 (1.4) 33.3 (3.2) 35.2 (4.4)
Smoking during pregnancy, n (%)a 96 (13.0%) 45 (12.2%) 38 (18.3%) 49 (14.6%) 19 (22.9%) 84 (24.1%)
Education, (%)b
Basic or less 27 (4.2%) 12 (3.6%) 8 (4.2%) 25 (8.1%) 5 (7.0%) 24 (7.8%)
Secondary 284 (43.8%) 123 (37.0%) 87 (46.0%) 139 (45.0%) 39 (54.9%) 176 (57.3%)
Lower-level tertiary 149 (23.0%) 93 (28.0%) 61 (32.3%) 88 (28.5%) 19 (26.8%) 74 (24.1%)
Upper-level tertiary 188 (29.0%) 104 (31.3%) 33 (17.5%) 57 (18.4%) 8 (11.3%) 33 (10.7%)
Primipara, n (%) 386 (52.1%) 180 (48.8%) 86 (41.3%) 131 (39.0%) 33 (39.8%) 144 (41.1%)
GWG, kgc 14.8 (4.6) 14.0 (5.1) 15.2 (5.5) 13.1 (5.4) 13.7 (7.5) 9.9 (6.0)
Excess GWGd, n (%) 250 (33.7%) 106 (28.7%) 159 (76.4%) 206 (61.3%) 61 (73.5%) 209 (59.7%)
GWG below recommendede, n (%) 184 (24.8%) 119 (32.2%) 13 (6.3%) 38 (11.3%) 8 (9.6%) 72 (20.6%)
Newborn
Birth weight, g 3,531 (461) 3,610 (469) 3,741 (451) 3,677 (469) 3,745 (495) 3,726 (486)
Birth weight SD −0.20 (0.96) 0.09 (1.02) 0.19 (0.94) 0.23 (1.04) 0.12 (1.03) 0.39 (1.22)
SGAf, n (%) 95 (12.8%) 38 (10.3%) 10 (4.8%) 28 (8.3%) 6 (7.2%) 28 (8.0%)
LGAg, n (%) 39 (5.3%) 31 (8.4%) 16 (7.7%) 38 (11.3%) 9 (10.8%) 60 (17.1%)
Gestational age at birth, weeks 40.1 (1.2) 39.8 (1.2) 40.3 (1.2) 39.8 (1.2) 40.5 (1.1) 39.7 (1.3)
GDM, gestational diabetes; BMI, body mass index (kg/m2 ); GWG, gestational weight gain.
aNumber of missing data in order of subgroups 1/1/0/1/0/2.
bNumber of missing data in order of subgroups 93/37/19/27/12/43.
cDifference of (self-reported) pre-pregnancy weight and weight at the last antenatal visit at 35 gestational weeks or later.
dExcess gestational weight gain based on the Institute of Medicine 2009 criteria.
eGestational weight gain below the Institute of Medicine 2009 criteria.
fSmall-for-gestational-age (birth weight under the 10th percentile for sex and gestational age).
gLarge-for-gestational-age (birth weight over the 90th percentile for sex and gestational age).
women with GDM, the prevalence of LGA was 10.8% in the diet-
treated group and 18.9% among women who received additional
medical treatment (p< 0.001). Among all women, pre-pregnancy
obesity increased the risk of LGA 1.75-fold (Table 4). In addition
to GDM and pre-pregnancy obesity, other independent risk
factors for LGA were a previous macrosomic newborn and
excess GWG.
Among all women, those with excess GWG had a 1.77-fold
odds for a LGA infant compared with women with normal GWG
(Table 4). Of the women with both GDM and obesity, the odds
for a LGA infant was 2.25-fold among those with normal GWG
and 7.63-fold among those with excess GWG compared with the
reference group (p < 0.001) (Figure 1).
Among normal weight and overweight GDM women, GWG
(normal/excess) was unrelated to the prevalence of LGA
(Figure 1). Among non-diabetic women, those with normal
pre-pregnancy BMI and normal GWG showed lower risk
for LGA than women with normal pre-pregnancy BMI and
excess GWG (p = 0.006). The results remained similar
regardless of whether the women with GWG below IOM
recommendations were included in the normal GWG group or
observed separately.
Birth Weight SD Scores
We assessed birth weight SD scores as continuous variables. In
general, they were lower whenGWGwas within the normal range
compared with excess GWG (Figure 1). Newborns of women
with GDM, obesity, and normal GWG had 0.71 SD (95% CI:
0.47–0.97) lower birth weight SD score than newborns of women
with GDM, obesity, and excess GWG. Newborns of normal
weight women with GDM and normal GWG had 0.28 SD (95%
CI: 0.05–0.51) lower birth weight SD score than newborns of
normal weight women with GDM and excess GWG. In addition,
newborns of normal weight non-diabetic women with normal
GWG had 0.46 SD (95% CI: 0.30–0.61) lower birth weight
SD score compared with their counterparts with excess GWG.
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TABLE 3 | Adjusteda odds ratios (ORs) and mean differences (95% CI) of mother’s and newborn’s characteristics as divided into five subgroups (2–6) compared with
normal weight non-diabetic women (subgroup 1).
Number of subgroup 2 3 4 5 6
GDM + BMI < 25.0 Non-diabetic + BMI 25.0–29.9 GDM + BMI 25.0–29.9 Non-diabetic + BMI ≥ 30.0 GDM + BMI ≥ 30.0
n = 369 n = 208 n = 336 n = 83 n = 350
OR/mean difference (95% CI)a
Mother
Age at delivery, years 2.3 (1.7–2.9) 1.2 (0.5–1.9) 2.7 (2.1–3.3) −0.1 (−1.2 to 0.9) 2.5 (1.9–3.1)
Height, cm −0.7 (−1.4 to 0.1) 0.08 (−0.8 to 1.0) −0.9 (−1.7 to −0.2) −0.2 (−1.5 to 1.1) −0.7 (−1.5 to 0.1)
Smoking during pregnancy 1.27 (0.86–1.88) 1.72 (1.12–2.64) 1.68 (1.14–2.48) 1.92 (1.08–3.42) 2.94 (2.08–4.17)
Primipara 1.17 (0.90–1.53) 0.74 (0.53–1.03) 0.83 (0.63–1.10) 0.58 (0.36–0.94) 0.89 (0.67–1.17)
GWG, kgb −0.5 (−1.2 to 0.1) 0.6 (−0.2 to 1.4) −1.2 (−1.9 to −0.6) −1.1 (−2.3 to 0.1) −4.5 (−5.2 to −3.9)
Excess GWGc 0.87 (0.66–1.16) 7.38 (5.13–10.6) 3.82 (2.88–5.07) 5.95 (3.52–10.0) 3.45 (2.61–4.56)
GWG below recommendedd 1.33 (1.00–1.76) 0.19 (0.11–0.34) 0.33 (0.23–0.49) 0.32 (0.15–0.68) 0.71 (0.51–0.98)
Newborn
Birth weight, g 69 (10–128) 194 (123–265) 123 (62–184) 201 (95–306) 183 (122–243)
Birth weight SD 0.29 (0.16–0.42) 0.40 (0.24–0.55) 0.43 (0.29–0.57) 0.33 (0.10–0.56) 0.60 (0.46–0.73)
SGAe 0.70 (0.46–1.05) 0.31 (0.16–0.61) 0.52 (0.33–0.82) 0.49 (0.21–1.16) 0.48 (0.31–0.76)
LGAf 1.59 (0.97–2.61) 1.48 (0.81–2.71) 2.09 (1.30–3.34) 2.14 (0.99–4.62) 3.56 (2.29–5.52)
Gestational age at birth, weeks −0.3 (−0.5 to −0.2) 0.2 (0.01–0.4) −0.3 (−0.5 to −0.2) 0.4 (0.1–0.7) −0.4 (−0.6 to −0.3)
GDM, gestational diabetes; BMI, body mass index (kg/m2 ); GWG, gestational weight gain.
aLinear regression for continuous variables and logistic regression for categorical variables adjusted for participant’s age at delivery, parity, smoking during pregnancy, and delivery hospital.
bDifference of (self-reported) pre-pregnancy weight and weight at the last antenatal visit at 35 gestational weeks or later.
cExcess gestational weight gain based on the Institute of Medicine 2009 criteria.
dGestational weight gain below the Institute of Medicine 2009 criteria.
eSmall-for-gestational-age (birth weight under the 10th percentile for sex and gestational age).
fLarge-for-gestational-age (birth weight over the 90th percentile for sex and gestational age).
Among women with GDM and overweight and among non-
diabetic women with overweight or obesity, these differences
were not statistically significant.
Small-for-Gestational Age
Among all women, GWG below the IOM recommendations
increased the odds for SGA 1.62-fold (95% CI: 1.14–2.31)
compared with women with normal GWG. The prevalence
of SGA was highest (12.8%) in the normal weight non-
diabetic women (Table 2). If their GWG was below the IOM
recommendation, the risk for SGA was 2.26-fold (95% CI: 1.37–
3.75) compared with their counterparts with normal GWG. In
the other groups, the increased risk for SGA was not seen in
women whose GWGwas under the IOM recommendations (data
not shown).
DISCUSSION
We found that normal GWG seems to protect from LGA and
lowers birth weight SD scores especially among the high-risk
women with GDM and pre-pregnancy obesity, but also among
non-diabetic women with normal weight. Excess GWG, GDM,
pre-pregnancy obesity, and a previous macrosomic newborn
were all independent risk factors for LGA.
The protective effect of normal GWG that we observed
was substantial. Among women with GDM and obesity, the
prevalence of LGAwasmore than halved whenGWGwas normal
compared with excess GWG (23.0 vs. 8.5%). All women in the
study cohort received lifestyle counseling after GDM diagnosis.
The lower GWG among GDM women with overweight/obesity
compared with their non-diabetic counterparts could reflect the
efficacy of diet counseling.
The optimal weight gain during pregnancy in women
diagnosed with GDM is unknown. A previous study among
women with GDM reported that modified, slightly restricted
GWG targets did not decrease the rate of LGA (11). That
study reported that almost half of the women with obesity
had already exceeded their IOM total GWG target by the
time of GDM diagnosis. In Finland, the national Current
Care Guidelines recommend that among women with obesity,
weight should not increase much more after GDM diagnosis
(14). Still, excess GWG was very common in women with
overweight/obesity regardless of their GDM status. These
findings suggest that early recognition of these high-risk
women and interventions aiming at maintaining normal
GWG may decrease the risk of pregnancy complications as
macrosomia. Also, excess GWG often leads to postpartum
weight retention, which increases risk for complications
in the woman’s subsequent pregnancies and her long-term
morbidity (3).
We found that insufficient GWG doubled the risk for SGA
in normal weight non-diabetic women, which is consistent
Frontiers in Public Health | www.frontiersin.org 5 May 2021 | Volume 9 | Article 550860
Mustaniemi et al. Risk Factors for Fetal Overgrowth
FIGURE 1 | Odds ratios (ORs) for large-for-gestational age (LGA) and mean differences for birthweight standard deviation (SD) scores in 12 subgroups categorized by
GDM status, pre-pregnancy BMI, and GWG (normal or excess); the group of non-diabetic women with normal pre-pregnancy BMI and with normal GWG was used as
a reference group. GDM, gestational diabetes; BMI, body mass index (kg/m2 ); GWG, gestational weight gain. Linear regression for continuous variables and logistic
regression for categorical variables adjusted for participant’s age at delivery, parity, smoking during pregnancy, and delivery hospital.
with a recent meta-analysis (17). However, GWG below the
recommendations did not increase the risk for SGA in normal
weight women with GDM or women with overweight/obesity
regardless of GDM status (data not shown), thus being in
line with a previous study (11). However, due to a relatively
small group of women with overweight/obesity and GWG below
the IOM recommendations, our results must be interpreted
with caution.
The main strengths of this study include a large, well-defined
clinical and homogenous study cohort (99.3% of women with
the Finnish ancestry). The GDM status of all participants was
confirmed from their medical records, and several potential
confounders were considered. We were also able to stratify our
analyses by pre-pregnancy BMI. The study provides high-quality
reference data of GWG in a relation with GDM status and fetal
overgrowth. There were also some limitations in this study. Due
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TABLE 4 | Crude and adjusted odds ratios (ORs) for risk factors of
large-for-gestational-age (LGA) (n = 2,087).
Risk factor Crude OR Adjusted ORa
GDM 2.11 (1.54–2.88) 1.59 (1.12–2.26)
Excess gestational weight
gainb
1.93 (1.42–2.62) 1.77 (1.29–2.43)
Pre-pregnancy BMI
25.0–29.9 kg/m2
1.11 (0.80–1.55) 0.81 (0.57–1.15)
Pre-pregnancy BMI ≥ 30.0
kg/m2
2.35 (1.71–3.22) 1.75 (1.24–2.47)
Age ≥ 35 years 1.65 (1.19–2.29) 1.03 (0.99–1.06)
Previous macrosomic
newborn > 4,500 g
6.76 (3.97–11.5) 7.31 (3.93–13.6)
GDM treated with insulin
and/or metformin
1.94 (1.27–2.96) 1.87 (1.18–2.96)
LGA, large-for-gestational-age (birth weight over the 90th percentile for sex and
gestational age); GDM, gestational diabetes; BMI, body mass index (kg/m2).
aAll adjusted models include participant’s age at delivery, parity, smoking during
pregnancy, delivery hospital, pre-pregnancy BMI, GDM, and GWG. As covariates, these
variables are entered as continuous except categorical variables: GDM, smoking during
pregnancy, and delivery hospital.
bExcess gestational weight gain based on the Institute of Medicine 2009 criteria.
to the low number of underweight women (n = 59, 2.8%),
they were categorized within the normal weight group. Thus,
the additional analysis was made after excluding underweight
women and findings did not change. Also, the number of women
with GWG below the recommendations was limited especially
those with overweight or obesity. Therefore, these women were
classified as having normal GWG in the final analysis. However,
the results were congruent regardless of whether the women
with GWG below recommendations were included in the normal
GWG group or observed separately. Another limitation was
the small number of non-diabetic women with obesity, and
especially, with normal GWG. Probably therefore, in this group,
the effect of normal GWG remained statistically non-significant.
In addition, pre-pregnancy weight was self-reported during the
first antenatal visit. This is common in similar studies, and as
mothers are measured at the first antenatal visit, substantial
reporting error is unlikely. Also the timing of GWG has been
reported relevant to fetal growth (18–20). Though excessive
GWG early in pregnancy has been reported to have the strongest
effect on fetal overgrowth (18, 19), also controversial results has
been presented (20). Thus, another limitation of the study is that
we were able to study only the total GWG during pregnancy, not
weight gain in different trimesters of pregnancy or after GDM
diagnosis. Although ethnically homogenous study population is
the strength of the study, the results may not be universally
applicable to other ethnic groups.
The diagnostic criteria still vary across the globe. In the
FinnGeDi study, the diagnosis of GDM was based on Finnish
Current Care Guidelines published in 2008 and revised in
2013 (14). This recommendation was primarily launched before
currently widely used the International Association of Diabetes
and Pregnancy Study Group (IADPSG) criteria were published
in 2010 (21). Based on Hyperglycaemia and Adverse Pregnancy
Outcome study (HAPO), the cut-offs for fasting glucose (≥
5.1 mmol/l) and 2 h glucose (≥ 8.5 mmol/l) are slightly lower
according to the IADPSG criteria. Thus, the prevalence of GDM
is slightly lower according to the Finnish criteria. In this study
population 62 women with fasting glucose 5.1–5.2 mmol/l would
have been diagnosed with GDM according to the IADPSG
criteria. No additional cases of GDM would have been found
based on 2 h value of 8.5 mmol/l. Thus, according to the Finnish
guidelines, only a small group of women was not diagnosed
with GDM and hence was not treated. The diagnostic criteria
used in this study, were and still are generally applied in the
whole Finland.
Normal GWG seems to decrease the risk for LGA especially
in GDM women with pre-pregnancy obesity and in non-diabetic
womenwith normal weight. Among both GDMand non-diabetic
women with normal weight, birth weight SD scores of the
newborns were lower when GWG was in the normal range.
Regardless of maternal glycemic status, effective prevention of
excess GWG, especially in women with obesity, is essential to
reduce fetal overgrowth.
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